VISCHER assists CRISPR Therapeutics in all Swiss law matters regarding a joint venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. Bayer will provide a minimum of USD 300 million in R&D investments to the JV over the next five years. In addition, Bayer will acquire a minority stake in CRISPR Therapeutics for USD 35 million in cash.

The team at VISCHER was led by Matthias Staehelin with Angelo Imperiale (both Corporate) and Nadia Tarolli (Tax).

Norton Rose Fulbright has advised London-listed Domino’s Pizza Group (DPG) on the establishment of a strategic joint venture (German JV) with Australian company Domino’s Pizza Enterprises (DPE).

Bayer and the Basel domiciled CRISPR Therapeutics AG have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. Bayer will provide a minimum of USD 300 million in R&D investments to the JV over the next five years.

Gilead Sciences Inc. entered into a global partnership with Galapagos NV in view of the further developing treatment of rheumatoid arthritis and other inflammatory diseases. Gilead Sciences Inc. invested USD 425 million equity in Galapagos and an additional USD 300 million in license fees. Arrangements on milestone and royalty payments have been set in place.

Eubelius assisted Gilead Sciences on the Belgian corporate aspect of the partnership, alongside Skadden Arps as global counsel. The Eubelius team was led by Marieke Wyckaert and Joris De Wolf.

Hannes Snellman has been engaged as counsel to YIT Corporation in the Mall of Tripla shopping centre project. YIT and Etera Mutual Pension Insurance Company, Onvest Oy, Fennia Mutual Insurance Company, and Fennia Life Insurance Company Ltd have signed a letter of intent on the establishment of a joint venture for the implementation of the Mall of Tripla and its parking facilities. The overall value of the shopping mall and the parking facility – the largest ever single asset transaction - is approximately EUR 600 million.

15 December 2015, China National Offshore Oil Corporation (CNOOC) signed an agreement with Royal Dutch Shell Group (Shell) to expand the capacity of the joint venture located in Huizhou City, Guangdong Province. According to the agreement, additional petrochemical production facilities will be built adjacent to the existing petrochemical complex and Shell will be involved in the construction process. CNOOC has already undertaken the construction of the petrochemical production facilities.

DLA Piper today announces that it represented the Canada Pension Plan Investment Board ("CPPIB") on the joint establishment of a US$500 million Korean logistics development platform, with APG Asset Management, Korean developer, owner and operator e-Shang, and its subsidiary, Kendall Square Logistics Properties (KSLP).   The deal includes an option to increase the size of the total equity commitment in the joint venture to US$ 1 billion over time.

We advised Tabcorp on its white label partnership with News to launch an online wagering and gaming business in the UK and Irish markets, to be known as "Sun Bets", in 2016.  The new business will bring together Tabcorp’s capability in global wagering with News UK’s vast customer base and market-leading media assets, including The Sun newspaper (print and digital properties) and associated sports and racing products (such as Dream Team FC, Favourite and Goals).  The agreement is structured as a revenue share arrangement with News UK undertaking internal and external me

Norton Rose Fulbright life sciences transactions team recently advised GSK in its development agreement and R&D collaboration with Propeller Health for GSK’s Ellipta® dry powder inhaler.

On December 3, 2015, Cytos Biotechnology AG (SIX: CYTN) (Cytos) and Kuros Biosurgery Holding AG (Kuros) announced their agreement to combine their businesses. The transaction is structured as a reverse merger in which Kuros' shareholders exchange their Kuros shares for new Cytos shares, subject to shareholder approval and other conditions.